ERIS Lifesciences' Q1 FY 2025-26 Quarterly Results

Result Summary

• ERIS Lifesciences Ltd reported a 37.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 7.5%.
• Its expenses for the quarter were up by 25.8% QoQ and 1.6% YoY.
• The net profit increased 57.1% QoQ and increased 39.9% YoY.
• The earnings per share (EPS) of ERIS Lifesciences Ltd stood at 8.6 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

ERIS Lifesciences Ltd is a prominent pharmaceutical company engaged in the development, manufacture, and marketing of a diverse range of pharmaceutical products. The company primarily operates in the chronic and acute therapeutic segments, offering formulations in areas such as cardiology, diabetes, gastroenterology, and dermatology. ERIS Lifesciences has established a significant presence in the Indian pharmaceutical market, leveraging its robust product portfolio and strategic marketing initiatives. While specific recent developments are not available, the company continues to focus on expanding its market reach and enhancing its product offerings to cater to evolving healthcare needs.

Revenue

In Q1FY26, ERIS Lifesciences Ltd reported a total income of ₹775.69 crores, marking a significant increase of 37.0% from ₹566.07 crores in Q4FY25. Compared to the same quarter in the previous fiscal year (Q1FY25), where total income was ₹721.36 crores, there was a year-over-year growth of 7.5%. This substantial growth in revenue highlights the company's strong performance over the quarters. The company's ability to generate consistent revenue growth is reflective of its strategic efforts in capturing market share and potentially expanding its product offerings.

Profitability

The company's profitability saw a notable improvement in Q1FY26. Profit Before Tax (PBT) for the quarter stood at ₹160.21 crores, representing a 109.0% increase from ₹76.65 crores in Q4FY25. On a year-over-year basis, PBT grew by 38.9% from ₹115.32 crores in Q1FY25. The Profit After Tax (PAT) followed a similar upward trajectory, reaching ₹125.10 crores in Q1FY26, up by 57.1% from ₹79.63 crores in the preceding quarter and by 39.9% from ₹89.42 crores in the same quarter last year. These improvements in profitability metrics indicate effective cost management and enhanced operational efficiency.

Operating Metrics

The company's total expenses for Q1FY26 were recorded at ₹615.48 crores, which increased by 25.8% from ₹489.42 crores in Q4FY25 and by 1.6% from ₹606.04 crores in Q1FY25. Despite the rise in expenses, the company's earnings per share (EPS) saw a significant increase to ₹8.60 in Q1FY26, compared to ₹5.20 in Q4FY25, marking a 65.4% quarter-over-quarter increase. On a year-over-year basis, EPS increased by 41.0% from ₹6.10 in Q1FY25. These operating metrics provide insights into the company's growth trajectory and its ability to maintain profitability amidst rising expenses.